What recent moves in Viatris (VTRS) might mean for investors

Viatris (VTRS) has drawn attention after recent share price moves, with the stock up over the past month and past 3 months, prompting investors to reassess how its fundamentals line up with today’s valuation.

The recent momentum in Viatris’ share price, with a 20.51% 1 month share price return and 50.61% 3 month share price return at a last close of $15.92, sits alongside a 48.70% 1 year total shareholder return. This suggests sentiment has shifted meaningfully as investors reassess both potential growth and perceived risks.

If this kind of move has you looking beyond a single name, it could be a good moment to scan 27 healthcare AI stocks as a starting list of other health related opportunities powered by AI trends.

With Viatris trading at $15.92 against an analyst target of about $14.11, despite an indicated intrinsic discount of roughly 69%, you have to ask: is this a genuine value gap, or is future growth already priced in?

Most Popular Narrative: 59.4% Undervalued

Viatris’ most followed narrative, according to Adje1959, sees a fair value of $39.24 per share versus the latest close at $15.92, a sizeable gap that frames a much more optimistic story than the current market price suggests.

The Viatris (VTRS) Story, with Bull Scenario Price Target

Viatris was created in 2020 through the merger of Mylan and Upjohn, Pfizer’s division of older, off patent medicines. Overnight it became one of the largest global players in generic drugs and biosimilars, operating in more than 165 countries. The early years were tough: many Upjohn products were in natural decline, the generics market is brutally competitive, and the merger came with a heavy debt load. Investors saw a company that needed to shrink rather than grow, and the stock lagged for years.

Beneath the surface, a different picture was developing. Viatris continued to generate substantial cash flows and used them to reduce debt, stabilize margins, and invest selectively in new areas such as biosimilars and cardiovascular treatments. One example is Inpefa, a heart failure medication gaining traction in the U.S. Despite the decline in legacy products, earnings per share have remained relatively stable, suggesting that the company may be operationally stronger than the market assumed.

Today, Viatris is described by this author as extremely undervalued, trading at a forward P/E around 5, offering a dividend, and showing what they view as signs of a sustained recovery. In this narrative, if the transformation continues, with growth in new products, further debt reduction, and a market rerating, the bull scenario price target sits between $16 and $18, reflecting what is seen as meaningful upside from the referenced levels.

In short, this thesis portrays Viatris as an underdog that was ignored for years but is now framed as more than a generics company. In this view it is a cash flow focused business in transition, with a low valuation, a dividend, and a bull case that the author believes sits well above the quoted price.

Curious how an underperforming merger story could be reframed as a cash flow engine in transition? The cited fair value rests on specific revenue paths, margin rebuild assumptions, and a future profit multiple that the author does not consider conservative. Interested in seeing exactly which earnings and valuation inputs are assumed to support a price more than double the level referenced in this narrative?

Result: Fair Value of $39.24 (UNDERVALUED)

However, this hinges on assumptions around revenue paths and margins, and any setback in newer products or slower debt reduction could quickly weaken that upbeat story.

Next Steps

With sentiment clearly mixed, do you want to rely on others’ assumptions or check the facts yourself, weigh the trade off between the concerns and potential upsides, and see how the balance of 3 key rewards and 2 important warning signs sits with you?

Looking for more investment ideas?

If Viatris has you thinking more broadly about where to put your money to work, do not stop here; you could miss alternatives better suited to your goals.

• Zero in on quality at a discount by checking our 54 high quality undervalued stocks that couple strong fundamentals with what appears to be mispriced share markets.
• Strengthen your income focus by scanning 15 dividend fortresses, where yields above 5% are paired with checks on balance sheet support and payout consistency.
• Prioritise staying power by reviewing a 87 resilient stocks with low risk scores that highlights companies with lower risk scores and more resilient financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.